Sensorimotor gating in neurotensin-1 receptor null mice

Neuropharmacology

Volumn 58, Issue 1, 2010, Pages 173-178

  Feifel, D ^a   Pang, Z ^b   Shilling, P D ^a   Melendez, G ^a   Schreiber, R ^b   Button, D ^b  

^a UCSD MEDICAL CENTER   (United States)

^b CNS Therapy Area   (United States)

Author keywords

Amphetamine; Animal model; Dizocilpine; Neurotensin; PD149163; Schizophrenia

Indexed keywords

AMPHETAMINE; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTENSIN 1 RECEPTOR; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST; PD 149163; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; STARTLE REFLEX; WILD TYPE;

ACOUSTIC STIMULATION; ADAMANTANE; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INDOLES; MICE; MICE, KNOCKOUT; NEURAL INHIBITION; NEUROPROTECTIVE AGENTS; RECEPTORS, NEUROTENSIN; SENSORY GATING; STARTLE REACTION;

EID: 71549118504     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.07.002     Document Type: Article

References (35)

1. Bakshi V.P., and Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 18 (1998) 8394-8401
2. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., and Nemeroff C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J. Neurosci. 21 (2001) 601-608
3. Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies [see comments]. Arch. Gen. Psychiatry. 47 (1990) 181-188
4. Caceda R., Kinkead B., Owens M.J., and Nemeroff C.B. Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. J. Neurosci. 25 (2005) 11748-11756
5. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., Lerch J.P., Trimble K., Uchiyama M., Sakuraba Y., Kaneda H., Shiroishi T., Houslay M.D., Henkelman R.M., Sled J.G., Gondo Y., Porteous D.J., and Roder J.C. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54 (2007) 387-402
6. Feifel D., Melendez G., Priebe K., and Shilling P.D. The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav. Brain Res. 81 (2007) 278-286
7. Feifel D., Melendez G., and Shilling P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29 (2004) 731-738
8. Feifel D., and Priebe K. Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol. Psychiatry 50 (2001) 425-433
9. Feifel D., Reza T.L., Wustrow D.J., and Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J. Pharmacol. Exp. Ther. 288 (1999) 710-713
10. Fradley R.L., O'Meara G.F., Newman R.J., Andrieux A., Job D., and Reynolds D.S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163 (2005) 257-264
11. Garver D.L., Bissette G., Yao J.K., and Nemeroff C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry. 148 (1991) 484-488
12. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
13. Hokfelt T., Everitt B.J., Theodorsson-Norheim E., and Goldstein M. Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol. 222 (1984) 543-559
14. Kanes S.J., Tokarczyk J., Siegel S.J., Bilker W., Abel T., and Kelly M.P. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144 (2007) 239-246
15. Kelly M.P., Isiegas C., Cheung Y.F., Tokarczyk J., Yang X., Esposito M.F., Rapoport D.A., Fabian S.A., Siegel S.J., Wand G., Houslay M.D., Kanes S.J., and Abel T. Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP. Neuropsychopharmacology 32 (2007) 577-588
16. Kelly M.P., Stein J.M., Vecsey C.G., Favilla C., Yang X., Bizily S.F., Esposito M.F., Wand G., Kanes S.J., and Abel T. Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia. Mol. Psychiatry 14 (2009) 398-415 347
17. Kinkead B., Dobner P.R., Egnatashvili V., Murray T., Deitemeyer N., and Nemeroff C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther. 315 (2005) 256-264
18. Kinkead B., and Nemeroff C.B. Neurotensin: an endogenous antipsychotic?. Curr. Opin. Pharmacol. 2 (2002) 99-103
19. Li J.H., Sicard F., Salam M.A., Baek M., LePrince J., Vaudry H., Kim K., Kwon H.B., and Seong J.Y. Molecular cloning and functional characterization of a type-I neurotensin receptor (NTR) and a novel NTR from the bullfrog brain. J. Mol. Endocrinol. 34 (2005) 793-807
20. Lindström L.H., Widerlöv E., Bisette G., and Nemeroff C. Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophrenia Res. 1 (1988) 55-59
21. Maeno H., Yamada K., Santo-Yamada Y., Aoki K., Sun Y.J., Sato E., Fukushima T., Ogura H., Araki T., Kamichi S., Kimura I., Yamano M., Maeno-Hikichi Y., Watase K., Aoki S., Kiyama H., Wada E., and Wada K. Comparison of mice deficient in the high- or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reveals a novel function for Ntsr2 in thermal nociception. Brain Res. 998 (2004) 122-129
22. Manberg P.J., Nemeroff C.B., Iversen L.L., Rosser M.N., Kizer J.S., and Prange Jr. A.J. Human brain distribution of neurotensin in normals, schizophrenics, and Huntington's choreics. Ann. N. Y Acad. Sci. 400 (1982) 354-367
23. Mansbach R.S., Geyer M.A., and Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94 (1988) 507-514
24. Mazella J., and Vincent J.P. Functional roles of the NTS2 and NTS3 receptors. Peptides 27 (2006) 2469-2475
25. Mechanic J.A., Sutton J.E., Berson A.E., Wu X., Kwan J., Schrieber R., Pang Z., and Button D.C. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: Lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice. Eur. Neuropsychopharmacology 19 7 (2009) 466-475
26. Nemeroff C.B., Bissette G., Widerlov E., Beckmann H., Gerner R., Manberg P.J., Lindstrom L., Prange Jr. A.J., and Gattaz W.F. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome. J. Neuropsychiatry Clin. Neurosciences 1 (1989) 16-20
27. Olivier B., Leahy C., Mullen T., Paylor R., Groppi V.E., Sarnyai Z., and Brunner D. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?. Psychopharmacology (Berl) 156 (2001) 284-290
28. Ouagazzal A.M., Jenck F., and Moreau J.L. Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity?. Psychopharmacology (Berl) 156 (2001) 273-283
29. Sharma R.P., Janicak P.G., Bissette G., and Nemeroff C.B. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 154 (1997) 1019-1021
30. Shilling P.D., and Feifel D. The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle. Pharmacol. Biochem. Behav. 90 (2008) 748-752
31. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., and Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet 71 (2002) 877-892
32. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophrenia Bull. 24 (1998) 285-301
33. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., and Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 63 (2006) 1325-1335
34. Widerlöv E., Lindström L.H., Besev G., Manberg P.J., Nemeroff C.B., Breese G.R., Kizer J.S., and Prange Jr. A.J. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am. J. Psychiatry. 139 (1982) 1122-1126
35. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., Okada-Iwabu M., Kawamoto S., Kubota N., Kubota T., Ito Y., Kamon J., Tsuchida A., Kumagai K., Kozono H., Hada Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Awazawa M., Takamoto I., Froguel P., Hara K., Tobe K., Nagai R., Ueki K., and Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13 (2007) 332-339